Assembly Biosciences, Inc.

Gilead Sciences, Inc. has historically focused on virology, with blockbuster products for HIV, hepatitis C and hepatitis B, but more recently has looked to broaden its therapeutic focus, particularly

Biopharmaceutical company valuations overall still are down by double digits year-to-date, but as the second quarter transitioned into the third stock prices have begun to rise across the industry as

Biologic candidates being developed under collaborations between big pharma and biotech are leading the race for novel hepatitis B (HBV) therapies as candidates under sole development increasingly dro

Viral disease-focused Antios Therapeutics Inc. hopes to move its active site polymerase inhibitor nucleotide (ASPIN) ATI-2173 into a 12-month Phase IIb study later this year, which could provide the